The incidence, risk factors and impact of acute kidney injury in hospitalized patients due to COVID-19.

The incidence of acute kidney injury (AKI) in hospitalized patients with COVID-19 is variable, being associated with worse outcomes. The objectives of the study were to evaluate the incidence, risk factors (considering demographic characteristics, comorbidities, initial clinical presentation and associated complications) and impact of AKI in subjects hospitalized for COVID-19 in two third-level hospitals in Córdoba, Argentina. A retrospective cohort study was conducted. We included 448 adults who were consecutively hospitalized for COVID-19 between March 3 and October 31, 2020 and were followed throughout the hospitalization. The incidence of AKI was 19% (n = 85; stage I = 43, stage II = 17, and stage III = 25, 18 required renal replacement therapy). In the multivariate analysis, the variables that were independently associated with AKI were: age (for every 10 years, adjusted odd ratio [95%CI] = 1.30 [1.04-1.63], p = 0.022), history of chronic kidney disease -CKD- (9.92 [4.52-21.77], p < 0.001), blood neutrophil count at admission -BNCA- (for every increase of 1000 BNCA, 1.09 [1.01-1.18], p = 0.037) and requirement for mechanical ventilation -MV- (6.69 [2.24-19.90], p = 0.001). AKI was associated with longer hospitalization, higher admission (63.5 vs. 29.7%; p < 0.001) and longer stay in the intensive care unit, a positive association with respiratory bacterial superinfection, sepsis, respiratory distress syndrome, MV requirement and mortality (mortality without AK I = 12.4% vs with AKI = 47.1%; stage I = 26%, stage II = 41% and stage III = 88%; p < 0.001). AKI was independently associated with higher mortality (3.32 [1.6-6.9], p = 0.001). In conclusion, the incidence of AKI in adults hospitalized for COVID-19 was 19% and had a clear impact on morbidity and mortality. The independent risk factors for AKI were: Age, CKD, BNCA and MV.

Los objetivos del estudio fueron evaluar la incidencia, los factores de riesgo (considerando características demográficas, comorbilidades, presentación clínica inicial y complicaciones asociadas) y el impacto de la lesión renal aguda ­LRA­ en sujetos hospitalizados por COVID-19 en dos instituciones de alta complejidad de Córdoba, Argentina. Se realizó un estudio de cohorte retrospectivo. Se incluyeron 448 adultos que fueron hospitalizados por COVID-19 entre el 3 de marzo y el 31 de octubre del 2020 con seguimiento durante toda la hospitalización. La incidencia de LRA fue 19% (estadio I = 43, estadio II = 17 y estadío III = 25, 18 requirieron diálisis). Las variables que se asociaron de manera independiente con el LRA fueron: edad (por cada 10 años, odd ratio ajustado [IC95%] = 1.30 [1.04-1.63], p = 0.022), enfermedad renal crónica ­ERC­ (9.92 [4.52-21.77], p < 0.001), recuento de neutrófilos sanguíneos al ingreso ­NSI­ (por cada incremento de 1000 NSI, 1.09 [1.01­1.18], p = 0.037) y asistencia respiratoria mecánica ­ARM­ (6.69 [2.24­19.90], p = 0.001). Los sujetos con LRA presentaron una internación más prolongada, mayor requerimiento (63.5 vs. 29.7%; p < 0.001) y estadía más prolongada en unidad de cuidados intensivos, una asociación positiva con sobreinfección respiratoria bacteriana, sepsis, síndrome de distrés respiratorio, requerimiento de ARM y mortalidad (mortalidad sin LRA 12.4% vs. con LRA 47.1%; estadio I = 26%, estadio II = 41% y estadio III = 88%; p < 0.001). LRA se asoció de manera independiente a mayor mortalidad (3.3 [1.6­6.9], p = 0.001). En conclusión, la incidencia de LRA en adultos hospitalizados por COVID-19 fue del 19% y tuvo un claro impacto en la morbi-mortalidad. Los factores de riesgo independientes de LRA fueron: edad, ERC, NSI y ARM.

The incidence, risk factors and impact of acute kidney injury in hospitalized patients due to COVID-19 / Incidencia, factores de riesgo e impacto de la lesión renal aguda en pacientes hospitalizados por COVID-19

Abstract The incidence of acute kidney injury (AKI) in hospitalized patients with COVID-19 is variable, being associated with worse outcomes. The objectives of the study were to evaluate the incidence, risk factors (considering demographic characteristics, comorbidities, initial clinical presentation and associated complications) and impact of AKI in subjects hospitalized for COVID-19 in two third-level hospitals in Córdoba, Argentina. A retrospective cohort study was conducted. We included 448 adults who were consecutively hospitalized for CO VID-19 between March 3 and October 31, 2020 and were followed throughout the hospitalization. The incidence of AKI was 19% (n = 85; stage I = 43, stage II = 17, and stage III = 25, 18 required renal replacement therapy). In the multivariate analysis, the variables that were independently associated with AKI were: age (for every 10 years, adjusted odd ratio [95%CI] = 1.30 [1.04-1.63], p = 0.022), history of chronic kidney disease -CKD- (9.92 [4.52-21.77], p < 0.001), blood neutrophil count at admission -BNCA- (for every increase of 1000 BNCA, 1.09 [1.01-1.18], p = 0.037) and requirement for mechanical ventilation -MV- (6.69 [2.24-19.90], p = 0.001). AKI was associated with longer hospitalization, higher admission (63.5 vs. 29.7%; p < 0.001) and longer stay in the intensive care unit, a positive association with respiratory bacterial superinfection, sepsis, respiratory distress syndrome, MV requirement and mortality (mortality without AK I = 12.4% vs with AKI = 47.1%; stage I = 26%, stage II = 41% and stage III = 88%; p < 0.001). AKI was independently associated with higher mortality (3.32 [1.6-6.9], p = 0.001). In conclusion, the incidence of AKI in adults hospitalized for COVID-19 was 19% and had a clear impact on morbidity and mortality. The independent risk factors for AKI were: Age, CKD, BNCA and MV.

Resumen Los objetivos del estudio fueron evaluar la incidencia, los factores de riesgo (consi derando características demográficas, comorbilidades, presentación clínica inicial y complicaciones asociadas) y el impacto de la lesión renal aguda -LRA- en sujetos hospitalizados por COVID-19 en dos instituciones de alta complejidad de Córdoba, Argentina. Se realizó un estudio de cohorte retrospectivo. Se incluyeron 448 adul tos que fueron hospitalizados por COVID-19 entre el 3 de marzo y el 31 de octubre del 2020 con seguimiento durante toda la hospitalización. La incidencia de LRA fue 19% (estadio I = 43, estadio II = 17 y estadío III = 25, 18 requirieron diálisis). Las variables que se asociaron de manera independiente con el LRA fueron: edad (por cada 10 años, odd ratio ajustado [IC95%] = 1.30 [1.04-1.63], p = 0.022), enfermedad renal crónica -ERC- (9.92 [4.52-21.77], p < 0.001), recuento de neutrófilos sanguíneos al ingreso -NSI- (por cada incremento de 1000 NSI, 1.09 [1.01-1.18], p = 0.037) y asistencia respiratoria mecánica -ARM- (6.69 [2.24-19.90], p = 0.001). Los sujetos con LRA presentaron una internación más prolongada, mayor requerimiento (63.5 vs. 29.7%; p < 0.001) y estadía más prolongada en unidad de cuidados intensivos, una asociación positiva con sobreinfección respi ratoria bacteriana, sepsis, síndrome de distrés respiratorio, requerimiento de ARM y mortalidad (mortalidad sin LRA 12.4% vs. con LRA 47.1%; estadio I = 26%, estadio II = 41% y estadio III = 88%; p < 0.001). LRA se asoció de manera independiente a mayor mortalidad (3.3 [1.6-6.9], p = 0.001). En conclusión, la incidencia de LRA en adultos hospitalizados por COVID-19 fue del 19% y tuvo un claro impacto en la morbi-mortalidad. Los factores de riesgo independientes de LRA fueron: edad, ERC, NSI y ARM.

Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action.

The International Society of Nephrology has adopted a proactive approach to defining the current state of kidney care and unmet needs through a multifaceted Closing the Gaps initiative. As part of this initiative, the International Society of Nephrology convened a meeting of experts to develop an approach to tackle acute kidney injury and chronic kidney disease (CKD). This manuscript expands on the recently published International Society of Nephrology CKD Roadmap and reports on the discussions of the working group assigned to the task of reviewing the global impact of complication of CKD. The working group defined the following goals: Goal 1: Optimize the management of anemia and endocrine and metabolic abnormalities associated with CKD. The impact of these conditions at a global level is not well understood, particularly in regions where renal replacement therapy is not readily available. Some treatment regimens may be affordable in low- and middle-income countries and if implemented, could have an impact on the burden of suffering associated with CKD. Goal 2: Improve the prevention and management of cardiovascular complications linked to CKD. Most research on cardiovascular complications of CKD has focused on atherosclerotic diseases (myocardial infarction, ischemic stroke, and peripheral gangrene). There has been growing recognition that other forms of cardiovascular diseases, such as heart failure, valvular disease and arrhythmias, have a major impact on patient outcomes. Much less is known about the mechanisms and treatment of these non-atherosclerotic complications. Goal 3: Improve the diagnosis and management of symptoms associated with CKD. Symptom management is one of the greatest challenges in the management of CKD, with limited knowledge about the mechanisms associated with the development of these common problems and how best to characterize them into usable clinical phenotypes. Improved understanding of the complications of CKD may alleviate suffering and prolong life among millions of people worldwide both in developed countries and in regions where renal replacement therapy is not widely available.

[The role of kidney transplantation in reducing mortality in a chronic dialysis program]. / Trasplante renal y disminución de la mortalidad en los programas de diálisis crónica.

For patients with chronic renal failure (CRF), kidney transplant (KT) is a better alternative to dialysis in terms of survival, life quality and costs. We studied the general characteristics, causes and survival rate of the dialysis population in 2010. We evaluated broader criteria for acceptance of transplants has affected the results of the procedure in that period. A total of 118 dialysis patients were included; mean age 56.9 ± 18.4 years, dialysis duration 45.5 ± 59.6 months, main cause of CRF was diabetes in 35 (30%), and 58 (49%) were included in waiting list for KT. Of the 34 patients who finished dialysis in 2010, 18 (53%) were KT, while 12 (35%) died (cardiovascular 50%, infectious 17%). Survival at 12 months was 85% for the total group, 98% on waiting list and 72% those who were not enrolled. During 2010 there were 88 KT, 62 with cadaveric donors (CD), 18 with living donors and 8 with double pancreas-kidney transplants. Recipients of CD were 50.7 years old, with 67 months on dialysis, 8 (13%) diabetics, and 12 (20%) with previous KT. Donors had a mean age of 45 years, 28 (45%) expanded criteria, and 27.7 hours of cold ischemia time. During an approximate follow-up of 11.4 months, 13 (21%) suffered acute graft rejection, survival was 88% for graft and 93% for patients. We emphasize KT as the main cause of success as regards dialysis. No differences in risk factors were found to significantly affect graft or patient survival.

Trasplante renal y disminución de la mortalidad en los programas de diálisis crónica / The role of kidney transplantation in reducing mortality in a chronic dialysis program

El trasplante renal (TR) presenta mejor supervivencia, calidad de vida y costos que la diálisis en la insuficiencia renal crónica (IRC). Estudiamos pacientes en diálisis que recibieron TR durante 2010, las causas de finalización del tratamiento y la supervivencia en diálisis. Evaluamos si criterios más amplios para la aceptación de trasplantes hubieran afectado los resultados del procedimiento en ese período. Incluimos 118 pacientes en diálisis, edad media 56.9 ± 18.4 años, tiempo en diálisis 45.5 ± 59.6 meses, 35 (30%) presentaban diabetes como causa de IRC, y 58 (49%) estaban en espera del TR. Treinta y cuatro finalizaron diálisis, 18 por TR y 12 por fallecimiento. Las principales causas de muerte fueron cardiovasculares, 6 (50%) e infecciones, 2 (17%). La supervivencia al año fue 85% para el grupo total, 98% para los pacientes inscriptos en lista de espera y 72% para no inscriptos. Durante 2010 se realizaron 88 TR (62 con donantes cadavéricos [DC], 18 donantes vivos y 8 dobles trasplantes páncreas-riñón). Los receptores de DC tenían en promedio 50.7 años, 67 meses en diálisis, 8 (13%) eran diabéticos, 12 (20%) con TR previos y 3 cross match contra panel de anticuerpos > 20%. Los donantes tenían edad media 45 años, 28 (45%) con criterios expandidos y 27.7 h de isquemia fría. A los 11.4 meses de seguimiento, 13 (21%) presentó rechazo agudo, la supervivencia para injerto fue de 88% y 93% para pacientes. La principal causa de finalización de diálisis fue TR, sin detectarse que el empleo de DC afectara la supervivencia del TR.

For patients with chronic renal failure (CRF), kidney transplant (KT) is a better alternative to dialysis in terms of survival, life quality and costs. We studied the general characteristics, causes and survival rate of the dialysis population in 2010. We evaluated broader criteria for acceptance of transplants has affected the results of the procedure in that period. A total of 118 dialysis patients were included; mean age 56.9 ± 18.4 years, dialysis duration 45.5 ± 59.6 months, main cause of CRF was diabetes in 35 (30%), and 58 (49%) were included in waiting list for KT. Of the 34 patients who finished dialysis in 2010, 18 (53%) were KT, while 12 (35%) died (cardiovascular 50%, infectious 17%). Survival at 12 months was 85% for the total group, 98% on waiting list and 72% those who were not enrolled. During 2010 there were 88 KT, 62 with cadaveric donors (CD), 18 with living donors and 8 with double pancreas-kidney transplants. Recipients of CD were 50.7 years old, with 67 months on dialysis, 8 (13%) diabetics, and 12 (20%) with previous KT. Donors had a mean age of 45 years, 28 (45%) expanded criteria, and 27.7 hours of cold ischemia time. During an approximate follow-up of 11.4 months, 13 (21%) suffered acute graft rejection, survival was 88% for graft and 93% for patients. We emphasize KT as the main cause of success as regards dialysis. No differences in risk factors were found to significantly affect graft or patient survival.

Trasplante renal y disminución de la mortalidad en los programas de diálisis crónica / The role of kidney transplantation in reducing mortality in a chronic dialysis program

El trasplante renal (TR) presenta mejor supervivencia, calidad de vida y costos que la diálisis en la insuficiencia renal crónica (IRC). Estudiamos pacientes en diálisis que recibieron TR durante 2010, las causas de finalización del tratamiento y la supervivencia en diálisis. Evaluamos si criterios más amplios para la aceptación de trasplantes hubieran afectado los resultados del procedimiento en ese período. Incluimos 118 pacientes en diálisis, edad media 56.9 ± 18.4 años, tiempo en diálisis 45.5 ± 59.6 meses, 35 (30%) presentaban diabetes como causa de IRC, y 58 (49%) estaban en espera del TR. Treinta y cuatro finalizaron diálisis, 18 por TR y 12 por fallecimiento. Las principales causas de muerte fueron cardiovasculares, 6 (50%) e infecciones, 2 (17%). La supervivencia al año fue 85% para el grupo total, 98% para los pacientes inscriptos en lista de espera y 72% para no inscriptos. Durante 2010 se realizaron 88 TR (62 con donantes cadavéricos [DC], 18 donantes vivos y 8 dobles trasplantes páncreas-riñón). Los receptores de DC tenían en promedio 50.7 años, 67 meses en diálisis, 8 (13%) eran diabéticos, 12 (20%) con TR previos y 3 cross match contra panel de anticuerpos > 20%. Los donantes tenían edad media 45 años, 28 (45%) con criterios expandidos y 27.7 h de isquemia fría. A los 11.4 meses de seguimiento, 13 (21%) presentó rechazo agudo, la supervivencia para injerto fue de 88% y 93% para pacientes. La principal causa de finalización de diálisis fue TR, sin detectarse que el empleo de DC afectara la supervivencia del TR.(AU)

For patients with chronic renal failure (CRF), kidney transplant (KT) is a better alternative to dialysis in terms of survival, life quality and costs. We studied the general characteristics, causes and survival rate of the dialysis population in 2010. We evaluated broader criteria for acceptance of transplants has affected the results of the procedure in that period. A total of 118 dialysis patients were included; mean age 56.9 ± 18.4 years, dialysis duration 45.5 ± 59.6 months, main cause of CRF was diabetes in 35 (30%), and 58 (49%) were included in waiting list for KT. Of the 34 patients who finished dialysis in 2010, 18 (53%) were KT, while 12 (35%) died (cardiovascular 50%, infectious 17%). Survival at 12 months was 85% for the total group, 98% on waiting list and 72% those who were not enrolled. During 2010 there were 88 KT, 62 with cadaveric donors (CD), 18 with living donors and 8 with double pancreas-kidney transplants. Recipients of CD were 50.7 years old, with 67 months on dialysis, 8 (13%) diabetics, and 12 (20%) with previous KT. Donors had a mean age of 45 years, 28 (45%) expanded criteria, and 27.7 hours of cold ischemia time. During an approximate follow-up of 11.4 months, 13 (21%) suffered acute graft rejection, survival was 88% for graft and 93% for patients. We emphasize KT as the main cause of success as regards dialysis. No differences in risk factors were found to significantly affect graft or patient survival.(AU)

Trasplante renal y disminución de la mortalidad en los programas de diálisis crónica. / [The role of kidney transplantation in reducing mortality in a chronic dialysis program].

For patients with chronic renal failure (CRF), kidney transplant (KT) is a better alternative to dialysis in terms of survival, life quality and costs. We studied the general characteristics, causes and survival rate of the dialysis population in 2010. We evaluated broader criteria for acceptance of transplants has affected the results of the procedure in that period. A total of 118 dialysis patients were included; mean age 56.9 ± 18.4 years, dialysis duration 45.5 ± 59.6 months, main cause of CRF was diabetes in 35 (30

), and 58 (49

) were included in waiting list for KT. Of the 34 patients who finished dialysis in 2010, 18 (53

) were KT, while 12 (35

) died (cardiovascular 50

, infectious 17

). Survival at 12 months was 85

for the total group, 98

on waiting list and 72

those who were not enrolled. During 2010 there were 88 KT, 62 with cadaveric donors (CD), 18 with living donors and 8 with double pancreas-kidney transplants. Recipients of CD were 50.7 years old, with 67 months on dialysis, 8 (13

) diabetics, and 12 (20

) with previous KT. Donors had a mean age of 45 years, 28 (45

) expanded criteria, and 27.7 hours of cold ischemia time. During an approximate follow-up of 11.4 months, 13 (21

) suffered acute graft rejection, survival was 88

for graft and 93

for patients. We emphasize KT as the main cause of success as regards dialysis. No differences in risk factors were found to significantly affect graft or patient survival.

High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.

BACKGROUND: There are few data in Argentina on the prevalence and management of bone and mineral metabolism (BMM) in patients with chronic kidney disease (CKD). OBJECTIVES AND METHODS: A survey was carried out in dialysis units in 2010 to measure the prevalence of and types of treatments for BMM disorders in Argentina. The data obtained was then compared to the published results from other large population studies. We recorded characteristics of dialysis centres and participating patients, the frequency of measurements and individual results for BMM biochemical markers, as well as the type of management used to control hyperphosphataemia and secondary hyperparathyroidism. RESULTS: 1210 patients from 25 dialysis centres in Argentina participated in the study (representing 4.7% of the country's prevalent dialysis population in 2010). The mean patient age was 55.3±17.6 years, 60.8% were male, 3.3% were on peritoneal dialysis and 29.1% suffered diabetes. In all centres, phosphataemia and calcaemia were measured on a monthly basis, 60% of centres measured intact parathyroid hormone (iPTH) every 6 months, 36% every 3 to 4 months, and 4% annually. As recommended by K/DOQI, 51.6% of patients had adequate levels of calcium (8.4-9.5 mg/dl), 51.6% had adequate phosphorus (3.5-5.5 mg/dl) and 21.1% displayed acceptable iPTH levels (150-300 pg/ml). 24% had iPTH <150 pg/ml and 54.5% >300 pg/ml. iPTH ≥600 pg/ml was present in 28.3%, and 13.3% had values ≥1000 pg/ml. These figures differed from those published by the DOPPS II study, in which 51.1% of patients had iPTH <150 pg/ml, and only 26.7% had iPTH ≥300 pg/ml. Calcium-based phosphate binders were used in 83.6% of the patients, 5.6% used sevelamer and 4.0% used aluminium-containing compounds. To achieve control of hyperparathyroidism, oral or intravenous calcitriol was predominantly used (50.5%) with a small percentage of patients receiving paricalcitol or doxercalciferol. CONCLUSIONS: The present study shows a high prevalence of secondary hyperparathyroidism, which differs from that published by other large population studies. There was a high proportion of patients with BMM markers outside the ranges suggested by K/DOQI. Mainly phosphate binders based on calcium and calcitriol continue to be used for the management of hyperphosphatemia and hyperparathyroidism respectively.

Elevada prevalencia de hiperparatiroidismo secundario en pacientes con enfermedad renal crónica en diálisis en Argentina / High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina

ANTECEDENTES: Existen pocos datos acerca de la prevalencia de los trastornos del metabolismo óseo y mineral (MOM) y su forma de manejo en pacientes con enfermedad renal crónica en Argentina. Objetivos y métodos: Mediante una encuesta realizada en 2010 en centros de diálisis, determinamos la prevalencia y las formas de tratamiento de los trastornos del MOM en Argentina y los comparamos con los datos publicados por otros grandes estudios poblacionales. Consignamos las características de los centros de diálisis y de los pacientes participantes, la frecuencia de las determinaciones y los resultados individuales de los marcadores bioquímicos del MOM y el tipo de manejo utilizado para controlar la hiperfosfatemia y el hiperparatiroidismo secundario. RESULTADOS: Participaron 1210 pacientes de 25 centros de diálisis de 10 provincias de Argentina (lo cual representaba el 4,7 % de la población prevalente en diálisis del país en 2010). La población estudiada tenía una edad media de 55,3 ± 17,6 años, 60,8 % eran varones, el 3,3 % en diálisis peritoneal y el 29,1 % eran diabéticos. El 100 % de los centros determinaban calcemia y fosfatemia mensualmente, el 60 % hormona paratiroidea intacta (PTHi) semestralmente, el 36 % cada 3 o 4 meses y el 4 % de forma anual. Según las recomendaciones de K/DOQI, el 51,6 % de los pacientes tenían niveles adecuados de calcio (8,4-9,5 mg/dl), el 51,6 % de fósforo (3,5-5,5 mg/dl) y el 21,1 % de PTHi (150 a 300 pg/ml). El 24,4 % tenían PTHi < 150 pg/ml y el 54,5 % > 300 pg/ml, con un 28,3 % con valores de PTHi > 600 pg/ml y un 13,3 % > 1000 pg/ml. Estos datos diferían de los publicados por el estudio DOPPS II, donde el 51,1 % de los pacientes presentaban PTHi < 150 pg/ml, y solo un 26,7 % PTHi > 300 pg/ml. El 83,6 % utilizaban un captor del fosfato basado en calcio, el 5,6 % sevelamer y el 4,0 % compuestos con aluminio. Para el control del hiperparatiroidismo se utilizaba predominantemente calcitriol oral o endovenoso (50,5 %), con un pequeño porcentaje de pacientes recibiendo paricalcitol o doxercalciferol. CONCLUSIONES: El presente estudio muestra una elevada prevalencia de hiperparatiroidismo secundario, lo cual difiere de lo publicado por otros grandes estudios poblacionales. Existe una elevada proporción de pacientes con marcadores del MOM por fuera de los niveles sugeridos por K/DOQI. Para el control de la hiperfosfatemia y el hiperparatiroidismo, se continúan utilizando mayormente captores del fosfato basados en calcio y calcitriol, respectivamente

BACKGROUND: There are few data in Argentina on the prevalence and management of bone and mineral metabolism (BMM) in patients with chronic kidney disease (CKD). Objectives and methods: A survey was carried out in dialysis units in 2010 to measure the prevalence of and types of treatments for BMM disorders in Argentina. The data obtained was then compared to the published results from other large population studies. We recorded characteristics of dialysis centres and participating patients, the frequency of measurements and individual results for BMM biochemical markers, as well as the type of management used to control hyperphosphataemia and secondary hyperparathyroidism. RESULTS: 1210 patients from 25 dialysis centres in Argentina participated in the study (representing 4.7% of the country's prevalent dialysis population in 2010). The mean patient age was 55.3±17.6 years, 60.8% were male, 3.3% were on peritoneal dialysis and 29.1% suffered diabetes. In all centres, phosphataemia and calcaemia were measured on a monthly basis, 60% of centres measured intact parathyroid hormone (iPTH) every 6 months, 36% every 3 to 4 months, and 4% annually. As recommended by K/DOQI, 51.6% of patients had adequate levels of calcium (8.4-9.5mg/dl), 51.6% had adequate phosphorus (3.5-5.5mg/dl) and 21.1% displayed acceptable iPTH levels (150-300pg/ml). 24% had iPTH <150pg/ml and 54.5% >300pg/ml. iPTH >600pg/ml was present in 28.3%, and 13.3% had values >1000pg/ml. These figures differed from those published by the DOPPS II study, in which 51.1% of patients had iPTH <150pg/ml, and only 26.7% had iPTH >300pg/ml. Calcium-based phosphate binders were used in 83.6% of the patients, 5.6% used sevelamer and 4.0% used aluminium-containing compounds. To achieve control of hyperparathyroidism, oral or intravenous calcitriol was predominantly used (50.5%) with a small percentage of patients receiving paricalcitol or doxercalciferol. CONCLUSIONS: The present study shows a high prevalence of secondary hyperparathyroidism, which differs from that published by other large population studies. There was a high proportion of patients with BMM markers outside the ranges suggested by K/DOQI. Mainly phosphate binders based on calcium and calcitriol continue to be used for the management of hyperphosphatemia and hyperparathyroidism respectively

Use of percutaneous ethanol injection therapy for recurrent secondary hyperparathyroidism after subtotal parathyroidectomy.

We evaluated the efficacy of percutaneous ethanol injection therapy (PEIT) as a therapeutic option for recurrence of secondary hyperparathyroidism after subtotal parathyroidectomy in ESRD patients. Six patients underwent PEIT. A mean of 1.3 ± 0.8 ethanol injections was performed. Nodular volume was 1.5 ± 1.7 cm(3), and 2.8 ± 2.8 cm(3) of ethanol was injected per patient. After ethanol injection PTH decreased significantly (1897 ± 754 to 549 ± 863 pg/mL (P < .01)). There was also a reduction in serum calcium, phosphorus and calcium-phosphorus product. A positive and significant correlation was found between nodular volume with ethanol injected and time from parathyroidectomy. Only one patient required hospitalization due to severe hypocalcaemia. In other two cases, local discomfort and temporary mild dysphonia were registered. PEIT is an effective treatment to control recurrences of secondary hyperparathyroidism postsubtotal parathyroidectomy.

Percutaneous ethanol injection therapy in post-transplant patients with secondary hyperparathyroidism.

Persistent hyperparathyroidism is frequent in postrenal transplant patients. Percutaneous ethanol injection therapy (PEIT) is an alternative for treatment of patients with secondary hyperparathyroidism but it was not described in postrenal transplant patients. We report our experience with PEIT to control hyperparathyroidism in the post-transplant period. We performed PEIT under ultrasonographic guidance and local anesthesia in eight patients because of persistent secondary hyperparathyroidism after renal transplantation. Indications for PEIT were: high intact parathyroid hormone (iPTH) levels with hypercalcemia, hypophosphatemia, osteopenia and/or bone pain. All patients had at least one visible parathyroid nodule by ultrasonography. Biochemical assays were performed immediately before PEIT, between 1 and 7 days after last PEIT, and a mean of 8.0 +/- 2.8 months after PEIT. Serum iPTH and calcium levels decreased significantly after treatment and remained unchanged until final control. Serum iPTH decreased from 286.9 +/- 107.2 to 154.6 +/- 42.2 pg/ml (P < 0.01) after PEIT (percentual reduction 36.5 +/- 9.5%). This response was significantly correlated to total ethanol volume used (r: 0.94, P < 0.0001). Hypercalcemia disappeared in six of eight patients treated. Only minor complications were registered. There were no changes in renal function related to the treatment. Our findings show that PEIT is a useful and safe alternative for patients with persistent post-transplant secondary hyperparathyroidism.

Alcoholización percutánea de glándulas paratiroideas: tratamiento del hiperparatiroidismo secundario, valoración de la eficacia según los niveles de la hormona paratiroidea / Percutánea fortification of paratiroideas glands: treatment of the secondary hiperparatiroidismo, valuation of the effectiveness according to the levels of paratiroidea hormone

Objetivo: La alcoholización percutánea de glándulas paratiroides (APGP)es una opción para el tratamiento de hiperparatiroidismo secundario. El objetivo de este trabajo es describir y determinar la seguridad y eficacia de esta técnica. Material y métodos: Fueron estudiados retrospecrivamente 45 pacientes con insuficiencia renal crónica terminal (IRCT) a los cuales se les realizó alcoholización percutánea de glándulas paratiroideas por contraindicación quirúrgica. Se analizaron los niveles de la hormona paratiroidea (PTH) antes del procedimiento, luego de la última diálisis (PTH-basal) y entre el 1º y 7º día posterior a la alcoholización (PTH-post alcoholización). Resultados: Diceiocho pacientes (47,4%) presentaron disminución de los valores de PTH en un 40% o más, considerándose el resultado del procedimiento exitoso u óptimo; en diez pacientes (26,3%), con una disminución de entre el 20% y el 40%, se valoró como sub-óptimo; en 6 pacientes (15,8%) no se obtuvieron resultados satisfactorios y en 4 pacientes (10,5%) no hubo modificación de los valores de PTH. Veintitrés pacientes del total (51,1%) presentaron complicaciones menores: disfonía (8,9%), dolor (35,6%), hematoma (2,2%), hipocalcemia(2,2%) y tos (2,2%). En ningún caso se presentaron complicaciones mayores. Conclusión: La APGP en los pacientes con hiperparatiroidismo secundario e IRCT es una opción segura y eficaz cuando no es factible la cirugía.

[Early urinary tract infection in kidney transplantation. Risk factors and impact on graft survival]. / Infección urinaria temprana en trasplante renal. Factores de riesgo y efecto en la sobrevida del injerto.

The early urinary tract infection (EUTI) in kidney transplant recipients is an infection develop during the first 3 months post transplant surgery. The effect of EUTI on graft survival and risk factors have been scarcely studied. Our objetives were the evaluation of risk factors to EUTI, the assessment of the causal agent and graft survival impact. A retrospective analysis of kidney transplantation, period 1997-2000 in Hospital Privado-Centro Médico de Córdoba was carried out. There were two groups of patients with (EUTI group) and without EUTI (control group). Cox model was used to analyze risk factors and Kaplan-Meier method for graft survival. A total of 226 consecutive patients received kidney transplantation. In 55 patients (24.3%) EUTI was detected. Risk factors for EUTI were: invasive urological maneuvers (RR = 4.34, CI 95% 1.42-13.21), diabetes mellitus (RR = 3.79, CI 95% 1.42-10.14), cytomegalovirus infection (RR = 2.9, CI 95% 1.02-8.24) and previous transplants (RR = 2.83, CI 95% 1.08-7.45). Delayed graft function was associated with lower incidence of EUTI (RR = 0.38, CI 95% 0.15-0.94). The causal agents were: Klebsiella pneumoniae (36%), Pseudomonas aeruginosa (24%) and Escherichia coli (9%). Graft survival at 2 years was similar in EUTI (87.2%) and control group (81.2%, p = 0.32). This series shows that invasive urological maneuvers were the main risk factors for EUTI. Graft survival was similar. High prevalence of non coli bacteria need further evaluation.

Infección urinaria temprana en trasplante renal. Factores de riesgo y efecto en la sobrevida del injerto. / [Early urinary tract infection in kidney transplantation. Risk factors and impact on graft survival]

The early urinary tract infection (EUTI) in kidney transplant recipients is an infection develop during the first 3 months post transplant surgery. The effect of EUTI on graft survival and risk factors have been scarcely studied. Our objetives were the evaluation of risk factors to EUTI, the assessment of the causal agent and graft survival impact. A retrospective analysis of kidney transplantation, period 1997-2000 in Hospital Privado-Centro Médico de Córdoba was carried out. There were two groups of patients with (EUTI group) and without EUTI (control group). Cox model was used to analyze risk factors and Kaplan-Meier method for graft survival. A total of 226 consecutive patients received kidney transplantation. In 55 patients (24.3

) EUTI was detected. Risk factors for EUTI were: invasive urological maneuvers (RR = 4.34, CI 95

1.42-13.21), diabetes mellitus (RR = 3.79, CI 95

1.42-10.14), cytomegalovirus infection (RR = 2.9, CI 95

1.02-8.24) and previous transplants (RR = 2.83, CI 95

1.08-7.45). Delayed graft function was associated with lower incidence of EUTI (RR = 0.38, CI 95

0.15-0.94). The causal agents were: Klebsiella pneumoniae (36

), Pseudomonas aeruginosa (24

) and Escherichia coli (9

). Graft survival at 2 years was similar in EUTI (87.2

) and control group (81.2

, p = 0.32). This series shows that invasive urological maneuvers were the main risk factors for EUTI. Graft survival was similar. High prevalence of non coli bacteria need further evaluation.

[Primary osteoporosis risk factors in women from Córdoba, Argentina]. / Factores de riesgo para osteoporosis primaria en mujeres de Córdoba, Argentina.

UNLABELLED: Risk factors for osteoporosis were evaluated in women from Cordoba, Argentina. Female patients that consulted about diagnosis or treatment of osteoporosis from January 2000 to June 2002 were included. Secondary osteoporosis patients were excluded. Participants were studied using standardized questionnaire, clinical examination, biochemical analysis, and dual-energy X-ray absorptiometry (DXA). According to lumbar spine DXA results and WHO criterion, we considered 2 groups: Osteoporosis (T score < -2.5 standard deviation, SD) and Control (T score > or = -2.5 SD). One hundred and fifty five women (Osteoporosis Group: 47; CONTROL GROUP: 108) were studied. In univariate analysis age, years from menopause, weight, smoking duration, estrogen replacement therapy duration, bilateral oophorectomy with hysterectomy, alkaline phosphatase levels, and Pouteau-Colles fractures were different between both groups. After multivariate analysis, including variables that were statistical different in univariate analysis, and considering osteoporosis as dependent variable, body weight (Odds Ratio, OR=0.92; CI 95% 0.87-0.98), alkaline phosphatase (OR=1.01; CI 95% 1.00-1.02), years from menopause (OR=1.12; CI 95% 1.05-1.21), and Pouteau-Colles fractures (OR=15.15; CI 95% 1.68-135.7) were independent risk factors for osteoporosis.

Factores de riesgo para osteoporosis primaria en mujeres de Córdoba, Argentina / Primary osteoporosis risk factors in women from Córdoba, Argentina

Estudiamos una serie de mujeres de la ciudad de Córdoba, Argentina, para definir los factores de riesgo clínicos prevalentes para osteoporosis lumbar. Se analizaron las pacientes que realizaron consulta en relación al diagnóstico o tratamiento de osteoporosis entre enero de 2000 y junio de 2002. Todas las pacientes fueron estudiadas mediante densitometría ósea de doble haz de rayos X , siendo excluidas del análisis aquellas con diagnóstico de osteoporosis secundaria. Según la densidad mineral ósea de columna lumbar se establecieron dos grupos de pacientes utilizando el criterio de la OMS: Grupo Osteoporosis (T score < -2.5 desvíos estándar, DE) y Grupo Control ( T score > = -2.5 DE) Se incluyeron 155 mujeres (47 en el Grupo Osteoporosis y 108 en el Grupo Control). El análisis univariado mostró diferencias estadísticas entre ambos grupos en: edad, años de posmenopausia, peso corporal , duración de tabaquismo, tiempo de utilizacvión de terapia estrigénica, anexectomía bilateral con histerectomía, niveles de fosfatasa alcalina y número de fracturas de muñeca (Pouteau-Clles). En el análisis multivariado, incluyendo las variablese que mostraron diferenciais significativas entre ambos grupos y considerando la presencia de osteoporosis como variable dependiente, el peso corporal (Odds Ratio, OR=0.92; IC 95% 0.87-0.98), la fosfatasa alcalina total (OR=1.01; CI 95% 1.00-1.02), los años de posmenopausa (OR=1.12; CI 95% 1.05-1.21), y el antecedente de fractura de muñeca (OR=15.15; CI 95% 1.68-135.7) fueron factores independientes que influyeron sobre el riesgo de padecer osteoporosis.

Factores de riesgo para osteoporosis primaria en mujeres de Córdoba, Argentina. / [Primary osteoporosis risk factors in women from Córdoba, Argentina]

Risk factors for osteoporosis were evaluated in women from Cordoba, Argentina. Female patients that consulted about diagnosis or treatment of osteoporosis from January 2000 to June 2002 were included. Secondary osteoporosis patients were excluded. Participants were studied using standardized questionnaire, clinical examination, biochemical analysis, and dual-energy X-ray absorptiometry (DXA). According to lumbar spine DXA results and WHO criterion, we considered 2 groups: Osteoporosis (T score < -2.5 standard deviation, SD) and Control (T score > or = -2.5 SD). One hundred and fifty five women (Osteoporosis Group: 47; Control Group: 108) were studied. In univariate analysis age, years from menopause, weight, smoking duration, estrogen replacement therapy duration, bilateral oophorectomy with hysterectomy, alkaline phosphatase levels, and Pouteau-Colles fractures were different between both groups. After multivariate analysis, including variables that were statistical different in univariate analysis, and considering osteoporosis as dependent variable, body weight (Odds Ratio, OR=0.92; CI 95

0.87-0.98), alkaline phosphatase (OR=1.01; CI 95

1.00-1.02), years from menopause (OR=1.12; CI 95

1.05-1.21), and Pouteau-Colles fractures (OR=15.15; CI 95

1.68-135.7) were independent risk factors for osteoporosis.

Factores de riesgo para osteoporosis primaria en mujeres de Córdoba, Argentina / Primary osteoporosis risk factors in women from Córdoba, Argentina

Estudiamos una serie de mujeres de la ciudad de Córdoba, Argentina, para definir los factores de riesgo clínicos prevalentes para osteoporosis lumbar. Se analizaron las pacientes que realizaron consulta en relación al diagnóstico o tratamiento de osteoporosis entre enero de 2000 y junio de 2002. Todas las pacientes fueron estudiadas mediante densitometría ósea de doble haz de rayos X , siendo excluidas del análisis aquellas con diagnóstico de osteoporosis secundaria. Según la densidad mineral ósea de columna lumbar se establecieron dos grupos de pacientes utilizando el criterio de la OMS: Grupo Osteoporosis (T score < -2.5 desvíos estándar, DE) y Grupo Control ( T score > = -2.5 DE) Se incluyeron 155 mujeres (47 en el Grupo Osteoporosis y 108 en el Grupo Control). El análisis univariado mostró diferencias estadísticas entre ambos grupos en: edad, años de posmenopausia, peso corporal , duración de tabaquismo, tiempo de utilizacvión de terapia estrigénica, anexectomía bilateral con histerectomía, niveles de fosfatasa alcalina y número de fracturas de muñeca (Pouteau-Clles). En el análisis multivariado, incluyendo las variablese que mostraron diferenciais significativas entre ambos grupos y considerando la presencia de osteoporosis como variable dependiente, el peso corporal (Odds Ratio, OR=0.92; IC 95% 0.87-0.98), la fosfatasa alcalina total (OR=1.01; CI 95% 1.00-1.02), los años de posmenopausa (OR=1.12; CI 95% 1.05-1.21), y el antecedente de fractura de muñeca (OR=15.15; CI 95% 1.68-135.7) fueron factores independientes que influyeron sobre el riesgo de padecer osteoporosis. (AU)